PS
NBIX icon

Principal Securities’s Neurocrine Biosciences NBIX Stock Holding History

Principal Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Buy
2,887
+1,353
+88% +$201K 0.01% 1087
2026
Q1 		$202K Buy
1,534
+6
+0.4% +$796 ﹤0.01% 1381
2025
Q4 		$217K Sell
1,528
-209
-12% -$30.3K ﹤0.01% 1289
2025
Q3 		$244K Buy
1,737
+22
+1% +$2.98K ﹤0.01% 1202
2025
Q2 		$216K Buy
1,715
+333
+24% +$38.2K ﹤0.01% 1206
2025
Q1 		$189K Hold
1,382
– – ﹤0.01% 1156
2024
Q4 		$189K Buy
1,382
+270
+24% +$33.4K ﹤0.01% 1156
2024
Q3 		$128K Buy
1,112
+219
+25% +$30K ﹤0.01% 1288
2024
Q2 		$123K Buy
893
+170
+24% +$23.3K ﹤0.01% 1236
2024
Q1 		$99.7K Buy
723
+151
+26% +$20.6K ﹤0.01% 1278
2023
Q4 		$75.4K Buy
+572
New +$65.8K ﹤0.01% 1302

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Principal Securities's NBIX Position: Q2 2026 in Review

Principal Securities increased its Neurocrine Biosciences (NBIX) stake by 88% in Q2 2026, buying an estimated $201K and bringing the position to 2,887 shares worth $487K. The position accounts for 0.01% of the portfolio, ranked #1087.

Principal Securities first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Principal Securities held 2,887 shares of Neurocrine Biosciences worth $487K as of Q2 2026.
  • Principal Securities bought 1,353 Neurocrine Biosciences shares in Q2 2026, an estimated $201K.
  • Neurocrine Biosciences made up 0.01% of Principal Securities's portfolio in Q2 2026, its #1087 holding.
  • Principal Securities first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.